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Long-term neurological conditions (LTNCs) often cause debilitating symptoms. Better understanding 
of symptom dimensions in LTNCs is needed to support health professionals and improve care. This 
can be achieved by exploring the factor structure of a standardised measure of symptoms in LTNC 
patients. The symptom subscale of the Integrated Palliative Outcome Scale for LTNCs (IPOS Neuro-S24) 
comprises 24 items measuring symptom severity. Descriptive statistics and psychometric properties 
of the scale were assessed, followed by differential item functioning (DIF), exploratory factor analysis 
(EFA) and confirmatory factor analysis (CFA). Data from N = 238 patients were analysed. The mean IPOS 
Neuro S-24 score was 27.0 (possible range 0–96) and floor effects were found for 21 items. The scale had 
good internal consistency (Cronbach’s alpha = 0.77). Weak evidence of DIF was found for nine items. All 
but one item (falls) loaded onto four factors with loadings > 0.3. The factors represented four clinically 
meaningful symptom dimensions: fatigue, motor symptoms, oral problems and non-motor symptoms. 
We identified a reliable four-factor structure of symptom experience in LTNC patients. The results 
suggest that symptom dimensions are common across LTNCs. The IPOS Neuro S-24 is an appropriate 
tool to measure symptoms in LTNC patients, which may improve care.
Long-term neurological conditions (LTNCs), including multiple sclerosis (MS), idiopathic Parkinson’s disease 
(IPD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and motor neurone disease (MND), 
are non-communicable, progressive diseases that can affect patients’ physical capability, sensory function, cogni-
tion, behaviour, communication and emotions1.
Research has previously underestimated the burden of LTNCs by considering only mortality and not disability 
related outcomes2, thus further research into the symptom experience of LTNC patients is warranted. Symptoms 
in LTNCs are common, multiple and insufficiently studied in the more advanced stages of disease, yet such infor-
mation is vital to improve care3–5.
Investigating patient symptomatology requires the use of a valid measurement tool. Exploring a measure’s psy-
chometric properties often includes identifying the tool’s internal consistency (a measure of scale reliability) and 
any floor and ceiling effects (where respondents excessively score at the lowest or highest end of the scale, respec-
tively). The psychometric development of a validated tool may also include factor analysis, a statistical approach 
to identifying the internal structure of a measure by exploring the relatedness of individual items.
Factor analysis has been used previously to assess symptom profiles for cancer6,7, heart failure, kidney dis-
ease8 and acute mania9. Assessing the factor structure of symptoms may contribute to the development of 
evidence-based diagnostic tools9. This could benefit both health professionals and patients, as care can be focused 
on managing groups of symptoms, rather than inefficiently treating single symptoms10.
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A previous factor analysis of eight symptoms in LTNC patients11 aimed to validate a shortened palliative care 
outcome measure for this patient group, but did not explore the factor structure of the whole spectrum of symp-
toms and identify clinically meaningful symptom clusters. No other studies have explored the factor structure of 
symptoms across LTNCs.
The present study aimed to explore the factor structure of a 24 item measure of symptoms in LTNC patients. 
It was hypothesised that, including a wider variety of symptoms, a factor analysis would identify a multi-factorial 
internal structure, which would illustrate distinct symptom dimensions across LTNCs.
Methods
sample. Patients were recruited for a trial investigating the effectiveness of a palliative care intervention from 
seven sites across the United Kingdom between April 2015 and August 2017 (the OPTCARE Neuro trial, NIHR 
trial registration number: ISRCTN18337380). Eligibility criteria were that patients had a diagnosis of either MS, 
Parkinsonism or related disorders (including IPD, PSP and MSA), or MND. Patients were also required not to 
have received specialist palliative care in the last six months, to have an unresolved symptom not responding to 
usual care and have at least one of the following: another unresolved symptom, cognitive problems or complex 
psychological/social needs. Patients were referred to the study by their neurology teams. The sample for the pres-
ent study was restricted to patients with complete symptom data at baseline.
Ethical approval and procedure. Ethical approval was obtained from the National Research Ethics Service 
Committee London South East (REC number: 14/LO/1765). All methods were performed in accordance with 
the relevant guidelines and regulations. After referral to the OPTCARE Neuro trial and the provision of a patient 
information leaflet, research nurses visited patients in their homes to obtain written informed consent and collect 
baseline data, using the Integrated Palliative Outcome Scale Neuro S-24 (IPOS Neuro S-24). Baseline data from 
the OPTCARE Neuro trial were used for this analysis.
Measures. IPOS Neuro S-24. The family of Palliative Outcome Scales (POS) measures the palliative care 
needs of patients12. The IPOS Neuro-S24 was developed to assess symptoms in LTNC patients. It includes 24 
symptom specific items, scored on a 5-point Likert scale from 0 (not at all) to 4 (overwhelmingly), where patients 
responded how they had been affected by that symptom in the last 3 days4. Symptoms included in the scale had 
previously been measured in MS, IPD, PSP and MSA patients13 and eight core symptoms showed promising 
psychometric properties following validation in MS, IPD, MSA and PSP patients (forming the IPOS Neuro-S8)11.
Data analysis. Descriptive analyses were used to describe item specific scores, using the mean and standard 
deviation. Frequency distributions for item-level responses scoring 0 (no problem) to 4 (overwhelmingly) were 
expressed as frequency and percentage. Floor and ceiling effects were measured by the number of respondents 
receiving the minimum (0) and maximum (4) score on the individual items. Floor and ceiling effects were deemed 
present when more than 15% of patients reported the extreme scores11. The internal consistency (an indicator of 
reliability) of the measure was calculated using Cronbach’s alpha coefficient. Differential Item Functioning (DIF) 
was used to identify differences (in individual item scores) between MS and IPD patients.
Exploratory factor analysis (EFA) was used to initially evaluate dimensions of the measure. As items were 
ordered categorical, polychoric correlation was used. EFA using principal factors extraction with oblique rota-
tion was performed. A scree plot and minimum Eigen value of 1.0 were used to identify the number of factors to 
retain; a minimum factor loading of 0.3 was also specified.
The EFA output was used to inform the confirmatory factor analysis (CFA). The CFA model fit was assessed 
using fit indices (RMSEA, SRMR, CFI and TLI). The following thresholds were used to indicate a good fitting 
model: RMSEA < 0.05, CFI > 0.95, TLI > 0.95 and SRMR < 0.0814,15. The modification indices command (estat 
mindices) was used to identify any further factor loadings or covarying error terms that would improve model fit; 
these were then added to the model. Correlation coefficients were used to assess correlation of factors. Parameters 
described by Evans et al.16 were used to classify weak (<0.4), moderate (0.4–0.59) and strong (>0.6) correlations. 
Stata 14 was used to perform data analysis.
Results
Sample characteristics. Data were collected from 350 patients; 284 had complete data for all 24 symp-
toms. Patients with incomplete symptom data (N = 66) were excluded. Patients lacking mental capacity (N = 39) 
were missing data as their data were collected via a carer and only patient-reported data were used in analysis, 
thus these data were missing at random (MAR). The remaining 17 patients with incomplete symptom data were 
missing data completely at random (MCAR). A further one patient was excluded as their diagnosis (‘other’) did 
not meet inclusion criteria. The analytical sample was 283. The descriptive statistics for the 67 excluded patients 
were comparable to the analytical sample: mean age = 67 years, 51% female, median years since diagnosis = 13, 
the majority were married, living with spouse, primary/secondary school educated and of white ethnicity. The 
characteristics of the analytical sample are presented in Table 1.
Descriptive statistics and psychometric properties. The mean total score of the IPOS Neuro-S24 was 
27.0 (SD = 10.3; Range 3–59) (possible range: 0–96). Kurtosis was 3.2 and skewness was 0.5, indicating near nor-
mal distribution, which was confirmed by visual inspection of a histogram. The highest scoring items were poor 
mobility, fatigue and problems using legs (see Table 2). The distributions of each item varied (following visual 
inspection of histograms for each item), some were normally distributed (feeling sleepy, fatigue, pain), whereas 
others were positively skewed (shortness of breath, problems using arms, dribbling saliva, amongst others). There 
was evidence for floor effects for all items except poor mobility, fatigue and problems using legs. Ceiling effects 
3Scientific RepoRts |          (2019) 9:4972  | https://doi.org/10.1038/s41598-019-41370-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Age Mean (SD) 66.6 (11.5)
Gender % Woman 48.4%
Diagnosis, N (%)
Multiple sclerosis 119 (42.1)
Idiopathic Parkinson’s disease 113 (39.9)
Multiple system atrophy 9 (3.2)
Progressive supranuclear palsy 20 (7.1)
Motor neurone disease 22 (7.8)
Duration of illness since diagnosis up 
to enrolment (in years)
Mean (SD) 12.9 (10.8)
Missing, N 1
Marital status, N (%)
Single 27 (9.5)
Widowed 32 (11.3)
Married/civil partner 188 (66.4)
Divorced/separated 35 (12.4)
Missing, N 1
Living arrangement, N (%)
Alone 54 (19.1)
With children 19 (6.7)
With spouse/partner 146 (51.6)
With spouse/partner and children 35 (12.4)
With friend(s) 3 (1.1)
Other 26 (9.2)
Educational attainment
Primary/lower secondary school 106 (37.6)
Upper secondary school/vocational training 100 (35.5)
Tertiary 76 (27.0)
Missing, N 1
Ethnicity
White 263 (92.9)
Black/African/Caribbean/black British 6 (2.1)
Other ethnic group 13 (4.6)
Prefer not to say 1 (0.4)
Table 1. Sample characteristics (N = 283).
Symptom Mean (SD)
0 (not at all) 
% (n)
1 (slightly) 
% (n)
2 (moderately) 
% (n)
3 (severely) 
% (n)
4 (over-
whelmingly) % (n)
Pain 1.6 (1.2) 23.7 (67) 21.2 (60) 30.4 (86) 21.6 (61) 3.2 (9)
Shortness of breath 0.8 (1.0) 50.5 (143) 25.1 (71) 18.7 (53) 4.2 (12) 1.4 (4)
Nausea 0.3 (0.7) 78.8 (223) 12.4 (35) 7.4 (21) 0.7 (2) 0.7 (2)
Vomiting <0.1 (0.4) 97.2 (275) 1.4 (4) 0.7 (2) — 0.7 (2)
Poor appetite 0.5 (1.0) 70.3 (199) 12.4 (35) 11.7 (33) 3.9 (11) 1.8 (5)
Constipation 1.2 (1.2) 37.1 (105) 19.1 (54) 28.3 (80) 13.1 (37) 2.5 (7)
Sore/dry mouth 1.0 (1.1) 47.0 (133) 17.0 (48) 25.1 (71) 8.5 (24) 2.5 (7)
Drowsiness 1.5 (1.1) 25.8 (73) 19.4 (55) 38.5 (109) 13.1 (37) 3.2 (9)
Poor mobility 2.8 (1.0) 3.9 (11) 6.7 (19) 22.3 (63) 41.7 (118) 25.4 (72)
Spasms 1.2 (1.2) 39.9 (113) 20.9 (59) 20.9 (59) 13.1 (37) 5.3 (15)
Fatigue 2.1 (1.1) 10.3 (29) 17.3 (49) 37.1 (105) 26.2 (74) 9.2 (26)
Problems swallowing 0.7 (1.0) 60.1 (170) 15.9 (45) 16.3 (46) 6.4 (18) 1.4 (4)
Feeling sleepy 1.8 (1.1) 16.6 (47) 20.5 (58) 35.0 (99) 21.6 (61) 6.4 (18)
Difficulty sleeping 1.1 (1.2) 48.4 (137) 14.1 (40) 22.6 (64) 12.0 (34) 2.8 (8)
Difficulty controlling bowels 0.9 (1.2) 54.1 (153) 21.2 (60) 12.4 (35) 7.1 (20) 5.3 (15)
Difficulty controlling urine 1.4 (1.3) 37.5 (106) 20.5 (58) 19.4 (55) 14.1 (40) 8.5 (24)
Pressure sores 0.3 (0.7) 84.5 (239) 7.0 (20) 5.3 (15) 2.5 (7) 0.7 (2)
Problems using arms 1.4 (1.2) 32.5 (92) 21.9 (62) 23.3 (66) 17.0 (48) 5.3 (15)
Problems using legs 2.6 (1.2) 8.8 (25) 9.2 (26) 19.1 (54) 39.6 (112) 23.3 (66)
Difficulty communicating 1.1 (1.1) 42.4 (120) 23.0 (65) 21.6 (61) 11.3 (32) 1.8 (5)
Dribbling saliva 0.9 (1.1) 49.8 (141) 23.7 (67) 13.8 (39) 10.3 (29) 2.5 (7)
Falls 0.8 (1.1) 60.4 (171) 16.6 (47) 13.1 (37) 7.1 (20) 2.8 (8)
Hallucinations 0.4 (0.8) 75.6 (214) 13.1 (37) 7.4 (21) 2.8 (8) 1.1 (3)
Mouth problems 0.6 (1.0) 69.3 (196) 13.4 (38) 10.3 (29) 5.3 (15) 1.8 (5)
Table 2. Frequency distribution of symptom scores.
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were seen only for poor mobility and problems using legs. The Cronbach’s alpha for the sample was 0.77, indicat-
ing good internal consistency.
Differential Item Functioning. Symptom scores were compared in MS and IPD patients (as the two 
biggest patient groups in this sample) using differential item functioning (DIF) analysis (results presented 
in Supplementary Material). Using a sub-sample of 196 MS (N = 119) and IPD (N = 113) patients, DIF was found 
for nine of the 24 items: patients with MS were more likely to report poor appetite, spasms, difficultly controlling 
bowels, problems using arms and problems using legs and patients with IPD were more likely to report difficulty 
communicating, dribbling saliva, hallucinations and mouth problems.
Factor analysis. The EFA retained eight factors after specifying a minimum eigen value of 1.0. However, less 
than 3 items loaded onto factors 5, 6, 7 and 8 (with factor loadings > 0.3), thus four factors were retained in the 
CFA. Falls was the only item to not load onto a factor and was excluded from the model.
Covarying error terms were added for the following items: drowsiness and feeling sleepy, poor mobility and 
problems using legs, sore/dry mouth and difficultly communicating, sore/dry mouth and dribbling saliva, sore/
dry mouth and mouth problems, nausea and vomiting. The final model is shown in Table 3.
The CFA produced a fairly good-fitting model, as indicated by the goodness of fit statistics (RMSEA = 0.045 
and SRMR = 0.064 both indicated a good fit, the CFI (0.894) and TLI (0.876) are approaching adequate fit). 
Moreover, this model was robust when repeated for MS and IPD patients independently (see Supplementary 
Material).
Factors were mostly weakly to moderately correlated. Fatigue related symptoms were moderately correlated 
with motor related symptoms (0.45) and strongly correlated with non-motor symptoms (0.62). Non-motor symp-
toms were moderately correlated with motor related symptoms (0.44) and oral problems (0.40). Oral problems 
were weakly correlated with fatigue related symptoms (0.23) and motor related symptoms (0.06).
Discussion
This is the first assessment of a range of symptoms across LTNCs using factor analysis, utilising baseline data from 
a multicentre clinical trial. The IPOS Neuro-S24 is a promising measure of symptoms across LTNCs and data 
using this measure produced a clinically meaningful four-factor model illustrating symptom dimensions related 
to fatigue, motor symptoms, oral problems and non-motor symptoms.
Factor One 
-Fatigue related 
symptoms
Factor Two 
-Motor related 
symptoms
Factor Three 
-Oral problems
Factor Four 
-Non-motor 
symptoms
Drowsiness 0.50 (0.06)
Fatigue 0.84 (0.05)
Feeling sleepy 0.63 (0.05)
Difficulty controlling urine 0.30 (0.06)
Constipation 0.30 (0.07)
Poor mobility 0.59 (0.06)
Spasms 0.50 (0.06)
Difficulty controlling bowels 0.42 (0.06)
Pressure sores 0.34 (0.07)
Problems using arms 0.59 (0.06)
Problems using legs 0.60 (0.06)
Sore/dry mouth 0.61 (0.08)
Problems swallowing 0.56 (0.06)
Difficulty communicating 0.62 (0.06)
Dribbling saliva 0.59 (0.06)
Hallucinations 0.30 (0.06)
Mouth problems 0.46 (0.06)
Pain 0.51 (0.06)
Shortness of breath 0.33 (0.07)
Nausea 0.51 (0.06)
Poor appetite 0.48 (0.06)
Vomiting 0.37 (0.07)
Difficulty sleeping 0.44 (0.06)
Falls
Fit statisticsa AIC = 17845.017, RMSEA = 0.045, CFI = 0.894, TLI = 0.876, SRMR = 0.064
Table 3. Confirmatory factor analysis; Standardised factor loadings (Standard error). aAIC – Akaike 
information criterion. RMSEA – Root mean square error of approximation. CFI – Confirmatory fit index. TLI – 
Tucker-Lewis Index. SRMR – Standardised root mean squared residual.
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The first factor predominantly included fatigue related symptoms. The factor loadings were generally high for 
these symptoms. Similar results were reported in a cluster analysis of symptoms in cancer patients17, as fatigue, 
lack of energy and weakness clustered together. Although the statistical techniques differed, it could be concluded 
that across these patient groups, these symptoms tend to appear together.
The second factor represented symptoms relating to motor control and mobility. Although difficulty con-
trolling bowels appears to be less similar to the other symptoms that load on to this factor, bowel problems may be 
a symptom of LTNCs due to nerve damage or loss of muscle control. Similarly, constipation can result from lack 
of physical activity. Problems relating to mobility frequently appear in the literature exploring symptomatology in 
LTNCs. In a systematic review of LTNC symptoms4, in 40 articles there were 18 different descriptors of mobility 
symptoms/problems and these symptoms were highly prevalent (>80% patients). The present study adds to this 
as the results demonstrate that symptoms presenting as the adverse effects of poor mobility (eg, pressure sores, 
constipation) load onto the same factor.
The third factor predominantly represented oral problems. Oral symptoms (including communication, swal-
lowing and dribbling/drooling) were presented by Saleem et al.4 as commonly reported symptoms in the LTNC 
literature. The present study adds to this by suggesting that these symptoms often co-occur.
The last factor included non-motor symptoms. It also included gastro-intestinal symptoms. These results are 
supported by Fink et al.18, who found a gastro-intestinal factor in their analysis of symptoms in patients from a 
neurology clinic, general medicine and primary care.
Although most symptoms that load onto factors fit within a logical ‘theme’, there were seemingly miscella-
neous symptoms, particularly difficulty controlling urine and hallucinations. Difficulty controlling urine loaded 
onto fatigue related symptoms, however this could be related to nocturia, muscle weakness and/or toileting prob-
lems due to poor mobility or lack of energy. Hallucinations, a neuropsychiatric non-motor symptom typically 
seen in IPD patients19, loaded onto oral problems. Swallowing dysfunction in IPD relates to more widespread 
Lewy bodies, or dry mouth due to anti-cholinergics may be a risk factor for confusion. Additionally, it is worth 
noting that many symptoms reported by patients may be related to treatments rather than the condition itself3. 
Thus, although factor analysis demonstrates where symptoms load onto common factors, it does not account for 
when one symptom might be caused by another, or may be symptomatic of a treatment for another symptom.
A key finding was the robustness of the factor model (and symptom dimensions) across different LTNCs. DIF 
was found for nine of the 24 items. However, it is worth noting that the Mantel-Haenszel tests used produced 
wide confidence intervals for spasms, problems using legs and hallucinations and mouth problems was borderline 
significant, indicating weak evidence for DIF. The CFA model fit the data (although to slightly less a degree) for 
MS and IPD patients independently. The models were comparable, however the fit statistics indicated the model 
fit the data best when using the whole sample, suggesting that the model was appropriate for use across LTNCs.
As this factor analysis was the first of its kind using a large number of motor and non-motor symptoms in this 
patient group, it is difficult to compare with other established measures. A factor analysis including patients with 
LTNCs using eight of the symptoms also used in the present study (pain, shortness of breath, nausea, vomiting, 
constipation, spasms, difficulty sleeping and mouth problems) reported a similar Cronbach’s alpha (0.66), also 
indicating good internal consistency11. As this scale comprised fewer items than the IPOS Neuro S-24, it pre-
sented fewer factors (two), which were not able to represent multiple symptom groups. It did, however, present 
good fit indices (SRMR = 0.057, RMSEA = 0.046), comparable to those seen in the present study. Two symptom 
measures identified in the literature17,18, each comprising 25 symptoms, though not using LTNC samples, demon-
strated how symptoms were likely to co-occur in different patient groups. In a factor analysis of symptoms in 
both neurological and general medical patients, three factors were observed: cardiopulmonary, musculoskeletal 
and gastrointestinal symptoms. In a cluster analysis of symptoms in patients with cancer, seven symptom clusters 
were identified. These findings suggest that including a wider range of symptoms in a measure has the benefit of 
demonstrating if and which symptoms are likely to co-occur by indicating a number of symptom groups.
These results have implications for care and research in LTNCs. This study demonstrates that symptom dimen-
sions are similar across LTNCs and that a single tool can be used to measure the outcome in this patient group. 
Moreover, the results may benefit clinical practice as symptom factors indicate that, where an individual reports 
experiencing one symptom, they are more likely to experience other symptoms that load on to the same factor. 
Better understanding of symptoms in LTNCs is necessary for the care of patients3–5, particularly palliative care, 
which is focused on symptom management and comfort. Previous research has found that collaborative working 
between neurology and palliative care professionals has room for improvement20; a palliative outcome measure 
specifically for patients with LTNCs could influence these working practices and patient outcomes in future.
This study benefitted from a relatively large clinical sample (N = 283) given that recruitment of palliative 
patients is difficult and numbers of LTNC patients are smaller compared to other incurable conditions. Potential 
limitations of the present study include exclusion of patients lacking capacity, as only patient-reported ratings 
were included in the factor analysis, and exclusion of patients with missing data. The IPOS Neuro-S24 comprises 
predominantly physical symptoms, rather than psychiatric, behavioural or cognitive symptoms. However, this 
was the nature of the measure, thus exploration of psychiatric, behavioural or cognitive symptoms was beyond 
the scope of this study.
The results from this study produced a reliable four-factor CFA model, using baseline data from a clinical 
sample of LTNC patients. Four stable symptom domains were identified: fatigue related symptoms, motor/mobil-
ity related symptoms, oral problems and gastric/other symptoms. Although floor effects were present, the IPOS 
Neuro S-24 showed promising psychometric properties and is an appropriate tool to measure symptoms in this 
patient group. This will enable health care providers to assess and monitor symptomatology in this patient group 
and provide appropriate and integrated neurological and palliative care.
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Data Availability
The datasets generated during and/or analysed during the current study are not publicly available due to being 
sourced from an ongoing, yet unpublished trial, but are available from the corresponding author on reasonable 
request.
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